Zhiming Mao, Michael J Betti, Miguel A Cedeno, Luis A Pedroza, Shamel Basaria, Qi Liu, Joseph M Choi, Janet G Markle
{"title":"Clinical and cellular phenotypes resulting from a founder mutation in IL10RB.","authors":"Zhiming Mao, Michael J Betti, Miguel A Cedeno, Luis A Pedroza, Shamel Basaria, Qi Liu, Joseph M Choi, Janet G Markle","doi":"10.1093/cei/uxad085","DOIUrl":null,"url":null,"abstract":"<p><p>Inborn errors of immunity are a group of rare genetically determined diseases that impair immune system development or function. Many of these diseases include immune dysregulation, autoimmunity, or autoinflammation as prominent clinical features. In some children diagnosed with very early onset inflammatory bowel disease (VEOIBD), monogenic inborn errors of immune dysregulation underlie disease. We report a case of VEOIBD caused by a novel homozygous loss of function mutation in IL10RB. We use cytometry by time-of-flight with a broad panel of antibodies to interrogate the immunophenotype of this patient and detect reduced frequencies of CD4 and CD8 T cells with additional defects in some populations of T helper cells, innate-like T cells, and memory B cells. Finally, we identify the patient's mutation as a founder allele in an isolated indigenous population and estimate the age of this variant by studying the shared ancestral haplotype.</p>","PeriodicalId":10268,"journal":{"name":"Clinical and experimental immunology","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11036105/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cei/uxad085","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Inborn errors of immunity are a group of rare genetically determined diseases that impair immune system development or function. Many of these diseases include immune dysregulation, autoimmunity, or autoinflammation as prominent clinical features. In some children diagnosed with very early onset inflammatory bowel disease (VEOIBD), monogenic inborn errors of immune dysregulation underlie disease. We report a case of VEOIBD caused by a novel homozygous loss of function mutation in IL10RB. We use cytometry by time-of-flight with a broad panel of antibodies to interrogate the immunophenotype of this patient and detect reduced frequencies of CD4 and CD8 T cells with additional defects in some populations of T helper cells, innate-like T cells, and memory B cells. Finally, we identify the patient's mutation as a founder allele in an isolated indigenous population and estimate the age of this variant by studying the shared ancestral haplotype.
先天性免疫错误是一组由基因决定的罕见疾病,会损害免疫系统的发育或功能。许多这类疾病都以免疫失调、自身免疫或自身炎症为主要临床特征。在一些被诊断为极早发炎性肠病(VEOIBD)的儿童中,单基因先天性免疫失调错误是疾病的基础。我们报告了一例由 IL10RB 的新型同基因功能缺失突变引起的 VEOIBD 病例。我们使用带有多种抗体的飞行时间细胞测定法来检测该患者的免疫表型,结果发现 CD4 和 CD8 T 细胞的频率降低,T 辅助细胞、先天性类 T 细胞和记忆 B 细胞的某些群体也存在缺陷。最后,我们确定该患者的变异是一个孤立的土著人群中的创始等位基因,并通过研究共享的祖先单倍型来估计该变异的年龄。
期刊介绍:
Clinical & Experimental Immunology (established in 1966) is an authoritative international journal publishing high-quality research studies in translational and clinical immunology that have the potential to transform our understanding of the immunopathology of human disease and/or change clinical practice.
The journal is focused on translational and clinical immunology and is among the foremost journals in this field, attracting high-quality papers from across the world. Translation is viewed as a process of applying ideas, insights and discoveries generated through scientific studies to the treatment, prevention or diagnosis of human disease. Clinical immunology has evolved as a field to encompass the application of state-of-the-art technologies such as next-generation sequencing, metagenomics and high-dimensional phenotyping to understand mechanisms that govern the outcomes of clinical trials.